Literature DB >> 32369172

Transplacental Respiratory Syncytial Virus and Influenza Virus Antibody Transfer in Alaska Native and Seattle Mother-Infant Pairs.

Helen Y Chu1, Kira L Newman1, Janet A Englund2,3, Shari Cho1, Catherine Bull3, Kirsten Lacombe3, Kristen Carlin3, Lisa R Bulkow4, Karen Rudolph4, Carolynn DeByle4, James Berner5, Joseph Klejka6, Rosalyn Singleton4,5.   

Abstract

BACKGROUND: Alaska Native (AN) infants are at risk for severe disease due to respiratory syncytial virus (RSV) and influenza. Maternal immunization protects young infants through transplacental antibody transfer. RSV- and influenza-specific transplacental antibody transfer in mother-infant pairs has not previously been evaluated in the AN population.
METHODS: Serum samples collected during pregnancy and at birth from AN mother-infant pairs in the Yukon-Kuskokwim Delta region (YKD) of Alaska (2000-2011; n = 75) and predominantly white pairs in Seattle, Washington (2014-2016; n = 57), were tested for RSV and influenza antibody using a microneutralization and hemagglutination inhibition assay, respectively, and compared between sites.
RESULTS: Mean RSV antibody concentrations in pregnant women in YKD and Seattle were similar (log2 RSV antibody 10.6 vs 10.7, P = .86), but cord blood RSV antibody concentrations were significantly lower in infants born to mothers in YKD compared with Seattle (log2 RSV antibody 11.0 vs 12.2, P < .001). Maternal and cord blood influenza antibody concentrations were lower for women and infants in YKD compared with Seattle for all 4 influenza antigens tested (all P < .05). The mean cord to maternal RSV antibody transfer ratio was 1.15 (standard deviation [SD], 0.13) in mother-infant pairs in Seattle compared with 1.04 (SD, 0.08) in YKD. Mean cord blood to maternal antibody transfer ratios for influenza antigens ranged from 1.22 to 1.42 in Seattle and from 1.05 to 1.59 in YKD.
CONCLUSIONS: Though the transplacental antibody transfer ratio was high (>1.0) for both groups, transfer ratios for RSV antibody were significantly lower in AN mother-infant pairs. Further studies are needed to elucidate the impact of lower transplacental antibody transfer on infant disease risk in rural Alaska.Alaska Native and continental US mother-infant pairs have high transplacental antibody transfer ratios (>1.0) for influenza and respiratory syncytial virus, but anti-respiratory syncytial virus antibody levels are significantly lower in Alaska Native pairs than in those from the continental US.
© The Author(s) 2020. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Alaska Native; influenza virus; maternal–child health; respiratory syncytial virus; transplacental antibody transfer

Year:  2021        PMID: 32369172     DOI: 10.1093/jpids/piaa040

Source DB:  PubMed          Journal:  J Pediatric Infect Dis Soc        ISSN: 2048-7193            Impact factor:   3.164


  3 in total

1.  Transplacental transfer of RSV antibody in Australian First Nations infants.

Authors:  Nusrat Homaira; Michael Binks; Gregory Walker; Natasha Larter; Katrina Clark; Megan Campbell; Lisa McHugh; Nancy Briggs; Joyce Nyiro; Sacha Stelzer-Braid; Nan Hu; Kristine Macartney; Tom Snelling; Saad B Omer; William Rawlinson; Ross Andrews; Adam Jaffe
Journal:  J Med Virol       Date:  2021-10-16       Impact factor: 20.693

Review 2.  Biological factors that may impair transplacental transfer of RSV antibodies: Implications for maternal immunization policy and research priorities for low- and middle-income countries.

Authors:  Jessica E Atwell; Chelsea S Lutz; Erin G Sparrow; Daniel R Feikin
Journal:  Vaccine       Date:  2022-06-17       Impact factor: 4.169

3.  Respiratory Syncytial Virus (RSV)-Specific Antibodies in Pregnant Women and Subsequent Risk of RSV Hospitalization in Young Infants.

Authors:  Karoliina Koivisto; Tea Nieminen; Asuncion Mejias; Cristina Capella Gonzalez; Fang Ye; Sara Mertz; Mark Peeples; Octavio Ramilo; Harri Saxén
Journal:  J Infect Dis       Date:  2022-04-01       Impact factor: 5.226

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.